Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.
Also see the archival list of Science's Compass: Enhanced Perspectives
CANCER: Enhanced: Addiction to Oncogenes--the Achilles Heal of Cancer
I. Bernard Weinstein
A series of recent studies are providing tantalizing hints of new therapeutic approaches for combating cancer. In his Perspective, Weinstein discusses new work (Jain et al.) demonstrating that even brief inactivation of an oncogene can permanently reverse the malignant phenotype of some types of tumor.
The author is at the Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10032, USA. E-mail: weinstei{at}cancercenter.columbia.edu
The editors suggest the following Related Resources on Science sites:
In Science Magazine
REPORTS
Meenakshi Jain, Constadina Arvanitis, Kenneth Chu, William Dewey, Edith Leonhardt, Maxine Trinh, Christopher D. Sundberg, J. Michael Bishop, and Dean W. Felsher (5 July 2002) Science297 (5578), 102.
[DOI: 10.1126/science.1071489] |Abstract »|Full Text »|PDF »|Supplemental Data »
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
The Constitutive Active/Androstane Receptor Facilitates Unique Phenobarbital-Induced Expression Changes of Genes Involved in Key Pathways in Precancerous Liver and Liver Tumors.
J. M. Phillips, L. D. Burgoon, and J. I. Goodman (2009)
Toxicol. Sci.
110, 319-333
|Abstract »|Full Text »|PDF »
Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma.
S. Komatsu, I. Imoto, H. Tsuda, K.-i. Kozaki, T. Muramatsu, Y. Shimada, S. Aiko, Y. Yoshizumi, D. Ichikawa, E. Otsuji, et al. (2009)
Carcinogenesis
30, 1139-1146
|Abstract »|Full Text »|PDF »
Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer.
D. C. Tomlinson, F. R. Lamont, S. D. Shnyder, and M. A. Knowles (2009)
Cancer Res.
69, 4613-4620
|Abstract »|Full Text »|PDF »
Expression levels of p18INK4C modify the cellular efficacy of cyclin-dependent kinase inhibitors via regulation of Mcl-1 expression in tumor cell lines.
T. Eguchi, H. Itadani, T. Shimomura, N. Kawanishi, H. Hirai, and H. Kotani (2009)
Mol. Cancer Ther.
8, 1460-1472
|Abstract »|Full Text »|PDF »
Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
D. J. Freeman, T. Bush, S. Ogbagabriel, B. Belmontes, T. Juan, C. Plewa, G. Van, C. Johnson, and R. Radinsky (2009)
Mol. Cancer Ther.
8, 1536-1546
|Abstract »|Full Text »|PDF »
Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities.
S. J. Horton, V. Walf-Vorderwulbecke, S. J. Chatters, N. J. Sebire, J. de Boer, and O. Williams (2009)
Blood
113, 4922-4929
|Abstract »|Full Text »|PDF »
Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
R. Chen, W. G. Wierda, S. Chubb, R. E. Hawtin, J. A. Fox, M. J. Keating, V. Gandhi, and W. Plunkett (2009)
Blood
113, 4637-4645
|Abstract »|Full Text »|PDF »
PPM1D Is a Potential Therapeutic Target in Ovarian Clear Cell Carcinomas.
D. S.P. Tan, M. B.K. Lambros, S. Rayter, R. Natrajan, R. Vatcheva, Q. Gao, C. Marchio, F. C. Geyer, K. Savage, S. Parry, et al. (2009)
Clin. Cancer Res.
15, 2269-2280
|Abstract »|Full Text »|PDF »
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer.
D. S. Hsu, C. R. Acharya, B. S. Balakumaran, R. F. Riedel, M. K. Kim, M. Stevenson, S. Tuchman, S. Mukherjee, W. Barry, H. K. Dressman, et al. (2009)
PNAS
106, 5312-5317
|Abstract »|Full Text »|PDF »
RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.
W.-I. Kim, I. Matise, M. D. Diers, and D. A. Largaespada (2009)
Blood
113, 1086-1096
|Abstract »|Full Text »|PDF »
Novel and Existing Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor are Predictors of Optimal Resectability in Malignant Peritoneal Mesothelioma.
J. M. Foster, Z. Gatalica, S. Lilleberg, G. Haynatzki, and B. W. Loggie (2009)
Ann. Surg. Oncol.
16, 152-158
|Abstract »|Full Text »|PDF »
A Novel Mechanism by Which Thiazolidinediones Facilitate the Proteasomal Degradation of Cyclin D1 in Cancer Cells.
S. Wei, H.-C. Yang, H.-C. Chuang, J. Yang, S. K. Kulp, P.-J. Lu, M.-D. Lai, and C.-S. Chen (2008)
J. Biol. Chem.
283, 26759-26770
|Abstract »|Full Text »|PDF »
Oncogenic NOTCH1 Control of MYC and PI3K: Challenges and Opportunities for Anti-NOTCH1 Therapy in T-Cell Acute Lymphoblastic Leukemias and Lymphomas.
Gefitinib Induction of In vivo Detectable Signals by Bcl-2/Bcl-xL Modulation of Inositol Trisphosphate Receptor Type 3.
A. Zannetti, F. Iommelli, R. Fonti, A. Papaccioli, J. Sommella, A. Lettieri, G. Pirozzi, R. Bianco, G. Tortora, M. Salvatore, et al. (2008)
Clin. Cancer Res.
14, 5209-5219
|Abstract »|Full Text »|PDF »
Endothelial Notch4 signaling induces hallmarks of brain arteriovenous malformations in mice.
P. A. Murphy, M. T. Y. Lam, X. Wu, T. N. Kim, S. M. Vartanian, A. W. Bollen, T. R. Carlson, and R. A. Wang (2008)
PNAS
105, 10901-10906
|Abstract »|Full Text »|PDF »
T. Shimamura, D. Li, H. Ji, H. J. Haringsma, E. Liniker, C. L. Borgman, A. M. Lowell, Y. Minami, K. McNamara, S. A. Perera, et al. (2008)
Cancer Res.
68, 5827-5838
|Abstract »|Full Text »|PDF »
EML4-ALK Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer.
J. P. Koivunen, C. Mermel, K. Zejnullahu, C. Murphy, E. Lifshits, A. J. Holmes, H. G. Choi, J. Kim, D. Chiang, R. Thomas, et al. (2008)
Clin. Cancer Res.
14, 4275-4283
|Abstract »|Full Text »|PDF »
Kaposi's Sarcoma-Associated Herpesvirus Confers a Survival Advantage to Endothelial Cells.
Oncogene Addiction versus Oncogene Amnesia: Perhaps More than Just a Bad Habit?.
D. W. Felsher, I. B. Weinstein, and A. Joe (2008)
Cancer Res.
68, 3081-3086
|Abstract »|Full Text »|PDF »
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.
D. B. Lipka, L. S. Hoffmann, F. Heidel, B. Markova, M.-C. Blum, F. Breitenbuecher, S. Kasper, T. Kindler, R. L. Levine, C. Huber, et al. (2008)
Mol. Cancer Ther.
7, 1176-1184
|Abstract »|Full Text »|PDF »
Integrative Approaches to Identify and Validate Kinase Oncogenes.
Genome-wide DNA copy number predictors of lapatinib sensitivity in tumor-derived cell lines.
J. Greshock, J. Cheng, D. Rusnak, A. M. Martin, R. Wooster, T. Gilmer, K. Lee, B. L. Weber, and T. Zaks (2008)
Mol. Cancer Ther.
7, 935-943
|Abstract »|Full Text »|PDF »
EBV LMP2A affects LMP1-mediated NF-{kappa}B signaling and survival of lymphoma cells by regulating TRAF2 expression.
Tumor Cell Killing Mechanisms of Epidermal Growth Factor Receptor (EGFR) Antibodies Are Not Affected by Lung Cancer-Associated EGFR Kinase Mutations.
M. Peipp, T. Schneider-Merck, M. Dechant, T. Beyer, J. J. Lammerts van Bueren, W. K. Bleeker, P. W. H. I. Parren, J. G. J. van de Winkel, and T. Valerius (2008)
J. Immunol.
180, 4338-4345
|Abstract »|Full Text »|PDF »
Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer Therapy.
J. R. Graff, B. W. Konicek, J. H. Carter, and E. G. Marcusson (2008)
Cancer Res.
68, 631-634
|Abstract »|Full Text »|PDF »
Signaling networks assembled by oncogenic EGFR and c-Met.
A. Guo, J. Villen, J. Kornhauser, K. A. Lee, M. P. Stokes, K. Rikova, A. Possemato, J. Nardone, G. Innocenti, R. Wetzel, et al. (2008)
PNAS
105, 692-697
|Abstract »|Full Text »|PDF »
Down-regulation of 14-3-3{zeta} suppresses anchorage-independent growth of lung cancer cells through anoikis activation.
Z. Li, J. Zhao, Y. Du, H. R. Park, S.-Y. Sun, L. Bernal-Mizrachi, A. Aitken, F. R. Khuri, and H. Fu (2008)
PNAS
105, 162-167
|Abstract »|Full Text »|PDF »
A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.
A. Duffy, J. Kortmansky, G. K. Schwartz, M. Capanu, S. Puleio, B. Minsky, L. Saltz, D. P. Kelsen, and E. M. O'Reilly (2008)
Ann. Onc.
19, 86-91
|Abstract »|Full Text »|PDF »
Oncogene addiction: setting the stage for molecularly targeted cancer therapy.
Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.
U. McDermott, S. V. Sharma, L. Dowell, P. Greninger, C. Montagut, J. Lamb, H. Archibald, R. Raudales, A. Tam, D. Lee, et al. (2007)
PNAS
104, 19936-19941
|Abstract »|Full Text »|PDF »
Targeting Protein Translation in Human Non Small Cell Lung Cancer via Combined MEK and Mammalian Target of Rapamycin Suppression.
M.-E. Legrier, C.-P. H. Yang, H.-G. Yan, L. Lopez-Barcons, S. M. Keller, R. Perez-Soler, S. B. Horwitz, and H. M. McDaid (2007)
Cancer Res.
67, 11300-11308
|Abstract »|Full Text »|PDF »
Bcl-2 Overexpression in Thyroid Carcinoma Cells Increases Sensitivity to Bcl-2 Homology 3 Domain Inhibition.
C. S. Mitsiades, P. Hayden, V. Kotoula, D. W. McMillin, C. McMullan, J. Negri, J. E. Delmore, V. Poulaki, and N. Mitsiades (2007)
J. Clin. Endocrinol. Metab.
92, 4845-4852
|Abstract »|Full Text »|PDF »
Activation of Hepatic Stem Cell Marker EpCAM by Wnt {beta}-Catenin Signaling in Hepatocellular Carcinoma.
T. Yamashita, A. Budhu, M. Forgues, and X. W. Wang (2007)
Cancer Res.
67, 10831-10839
|Abstract »|Full Text »|PDF »
Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer.
J. Kendall, Q. Liu, A. Bakleh, A. Krasnitz, K. C. Q. Nguyen, B. Lakshmi, W. L. Gerald, S. Powers, and D. Mu (2007)
PNAS
104, 16663-16668
|Abstract »|Full Text »|PDF »
Nek2 as an Effective Target for Inhibition of Tumorigenic Growth and Peritoneal Dissemination of Cholangiocarcinoma.
T. Kokuryo, T. Senga, Y. Yokoyama, M. Nagino, Y. Nimura, and M. Hamaguchi (2007)
Cancer Res.
67, 9637-9642
|Abstract »|Full Text »|PDF »
Multiple Myeloma Cell Killing by Depletion of the MET Receptor Tyrosine Kinase.
C. M. Stellrecht, C. J. Phillip, F. Cervantes-Gomez, and V. Gandhi (2007)
Cancer Res.
67, 9913-9920
|Abstract »|Full Text »|PDF »
Histological and proteomic analysis of reversible H-RasV12G expression in transgenic mouse skin.
W.-J. Oh, V. Rishi, S. Pelech, and C. Vinson (2007)
Carcinogenesis
28, 2244-2252
|Abstract »|Full Text »|PDF »
Targeting the Cytoplasmic and Nuclear Functions of Signal Transducers and Activators of Transcription 3 for Cancer Therapy.
Lipid rafts are required for Kit survival and proliferation signals.
T. Jahn, E. Leifheit, S. Gooch, S. Sindhu, and K. Weinberg (2007)
Blood
110, 1739-1747
|Abstract »|Full Text »|PDF »
Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus.
G. J. Riely, M. G. Kris, B. Zhao, T. Akhurst, D. T. Milton, E. Moore, L. Tyson, W. Pao, N. A. Rizvi, L. H. Schwartz, et al. (2007)
Clin. Cancer Res.
13, 5150-5155
|Abstract »|Full Text »|PDF »
Inhibition of Mammalian Target of Rapamycin Signaling by 2-(Morpholin-1-yl)pyrimido[2,1-{alpha}]isoquinolin-4-one.
L. M. Ballou, E. S. Selinger, J. Y. Choi, D. G. Drueckhammer, and R. Z. Lin (2007)
J. Biol. Chem.
282, 24463-24470
|Abstract »|Full Text »|PDF »
Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.
C.-H. Wu, J. van Riggelen, A. Yetil, A. C. Fan, P. Bachireddy, and D. W. Felsher (2007)
PNAS
104, 13028-13033
|Abstract »|Full Text »|PDF »
Oncogenic Activity of Epidermal Growth Factor Receptor Kinase Mutant Alleles Is Enhanced by the T790M Drug Resistance Mutation.
N. Godin-Heymann, I. Bryant, M. N. Rivera, L. Ulkus, D. W. Bell, D. J. Riese II, J. Settleman, and D. A. Haber (2007)
Cancer Res.
67, 7319-7326
|Abstract »|Full Text »|PDF »
Molecular Pathways for Cancer Angioprevention.
A. Albini, D. M. Noonan, and N. Ferrari (2007)
Clin. Cancer Res.
13, 4320-4325
|Abstract »|Full Text »|PDF »
Pancreatic Cancer Epidermal Growth Factor Receptor (EGFR) Intron 1 Polymorphism Influences Postoperative Patient Survival and in vitro Erlotinib Response.
C.-W. D. Tzeng, A. Frolov, N. Frolova, N. C. Jhala, J. H. Howard, S. M. Vickers, D. J. Buchsbaum, M. J. Heslin, and J. P. Arnoletti (2007)
Ann. Surg. Oncol.
14, 2150-2158
|Abstract »|Full Text »|PDF »
Lineage-Specific Dependency of Lung Adenocarcinomas on the Lung Development Regulator TTF-1.
H. Tanaka, K. Yanagisawa, K. Shinjo, A. Taguchi, K. Maeno, S. Tomida, Y. Shimada, H. Osada, T. Kosaka, H. Matsubara, et al. (2007)
Cancer Res.
67, 6007-6011
|Abstract »|Full Text »|PDF »
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al. (2007)
Mol. Cancer Ther.
6, 2065-2072
|Abstract »|Full Text »|PDF »
Sensitizing HER2-overexpressing cancer cells to luteolin-induced apoptosis through suppressing p21WAF1/CIP1 expression with rapamycin.
C.-T. Chiang, T.-D. Way, and J.-K. Lin (2007)
Mol. Cancer Ther.
6, 2127-2138
|Abstract »|Full Text »|PDF »
Chemoresistant KM12C Colon Cancer Cells Are Addicted to Low Cyclic AMP Levels in a Phosphodiesterase 4-Regulated Compartment via Effects on Phosphoinositide 3-Kinase.
D. G. McEwan, V. G. Brunton, G. S. Baillie, N. R. Leslie, M. D. Houslay, and M. C. Frame (2007)
Cancer Res.
67, 5248-5257
|Abstract »|Full Text »|PDF »
Metastatic Potential of 21T Human Breast Cancer Cells Depends on Akt/Protein Kinase B Activation.
M. Qiao, J. D. Iglehart, and A. B. Pardee (2007)
Cancer Res.
67, 5293-5299
|Abstract »|Full Text »|PDF »
J. Wang, K. Kuropatwinski, J. Hauser, M. R. Rossi, Y. Zhou, A. Conway, J. L.C. Kan, N. W. Gibson, J. K.V. Willson, J. K. Cowell, et al. (2007)
Mol. Cancer Ther.
6, 1143-1150
|Abstract »|Full Text »|PDF »
Tumor Growth Inhibition with Cetuximab and Chemotherapy in Non-Small Cell Lung Cancer Xenografts Expressing Wild-type and Mutated Epidermal Growth Factor Receptor.
P. Steiner, C. Joynes, R. Bassi, S. Wang, J. R. Tonra, Y. R. Hadari, and D. J. Hicklin (2007)
Clin. Cancer Res.
13, 1540-1551
|Abstract »|Full Text »|PDF »
PTEN-Mediated Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors.
I. K. Mellinghoff, T. F. Cloughesy, and P. S. Mischel (2007)
Clin. Cancer Res.
13, 378-381
|Abstract »|Full Text »|PDF »
A Sequential Blockade Strategy for the Design of Combination Therapies to Overcome Oncogene Addiction in Chronic Myelogenous Leukemia..
Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch.
S. Giuriato, S. Ryeom, A. C. Fan, P. Bachireddy, R. C. Lynch, M. J. Rioth, J. van Riggelen, A. M. Kopelman, E. Passegue, F. Tang, et al. (2006)
PNAS
103, 16266-16271
|Abstract »|Full Text »|PDF »
Molecular On/Off Switch.
D. T. Milton, G. J. Riely, W. Pao, V. A. Miller, M. G. Kris, and R. T. Heelan (2006)
J. Clin. Oncol.
24, 4940-4942
|Full Text »|PDF »
Squamous Cell Carcinoma Related Oncogene/DCUN1D1 Is Highly Conserved and Activated by Amplification in Squamous Cell Carcinomas.
I. Sarkaria, P. O-charoenrat, S. G. Talbot, P. G. Reddy, I. Ngai, E. Maghami, K. N. Patel, B. Lee, Y. Yonekawa, M. Dudas, et al. (2006)
Cancer Res.
66, 9437-9444
|Abstract »|Full Text »|PDF »
Identification of a Chemical Inhibitor of the Oncogenic Transcription Factor Forkhead Box M1.
S. K. Radhakrishnan, U. G. Bhat, D. E. Hughes, I-C. Wang, R. H. Costa, and A. L. Gartel (2006)
Cancer Res.
66, 9731-9735
|Abstract »|Full Text »|PDF »
Developing gene expression signatures of pathway deregulation in tumors..
Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo..
H.-G. Wendel, A. Malina, Z. Zhao, L. Zender, S. C. Kogan, C. Cordon-Cardo, J. Pelletier, and S. W. Lowe (2006)
Cancer Res.
66, 7639-7646
|Abstract »|Full Text »|PDF »
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas..
E. L. Kwak, J. Jankowski, S. P. Thayer, G. Y. Lauwers, B. W. Brannigan, P. L. Harris, R. A. Okimoto, S. M. Haserlat, D. R. Driscoll, D. Ferry, et al. (2006)
Clin. Cancer Res.
12, 4283-4287
|Abstract »|Full Text »|PDF »
"Oncogenic Shock": Explaining Oncogene Addiction through Differential Signal Attenuation..
S. V. Sharma, M. A. Fischbach, D. A. Haber, and J. Settleman (2006)
Clin. Cancer Res.
12, 4392s-4395s
|Abstract »|Full Text »|PDF »
A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer.
Y. Yatabe, T. Hida, Y. Horio, T. Kosaka, T. Takahashi, and T. Mitsudomi (2006)
J. Mol. Diagn.
8, 335-341
|Abstract »|Full Text »|PDF »
Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward.
G. J. Kelloff, S. M. Lippman, A. J. Dannenberg, C. C. Sigman, H. L. Pearce, B. J. Reid, E. Szabo, V. C. Jordan, M. R. Spitz, G. B. Mills, et al. (2006)
Clin. Cancer Res.
12, 3661-3697
|Abstract »|Full Text »|PDF »
SV40 T/t-Common Polypeptide Specifically Induces Apoptosis in Human Cancer Cells that Overexpress HER2/neu.
C.-C. Wen, S.-A. Cheng, S.-P. Hsuen, Y.-L. Huang, Z.-K. Kuo, H.-F. Lee, C.-H. Kuo, J.-L. Du, and W.-B. Wang (2006)
Cancer Res.
66, 5847-5857
|Abstract »|Full Text »|PDF »
Loss of p53 impedes the antileukemic response to BCR-ABL inhibition.
H.-G. Wendel, E. de Stanchina, E. Cepero, S. Ray, M. Emig, J. S. Fridman, D. R. Veach, W. G. Bornmann, B. Clarkson, W. R. McCombie, et al. (2006)
PNAS
103, 7444-7449
|Abstract »|Full Text »|PDF »
Construction of a novel DNA decoy that inhibits the oncogenic {beta}-catenin/T-cell factor pathway..
Y. Seki, H. Yamamoto, C. Yee Ngan, M. Yasui, N. Tomita, K. Kitani, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, et al. (2006)
Mol. Cancer Ther.
5, 985-994
|Abstract »|Full Text »|PDF »
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor..
J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank (2006)
Cancer Res.
66, 3162-3168
|Abstract »|Full Text »|PDF »
From integrated genomics to tumor lineage dependency..
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.
G. A. Smolen, R. Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, W. J. Kim, R. A. Okimoto, D. W. Bell, D. C. Sgroi, et al. (2006)
PNAS
103, 2316-2321
|Abstract »|Full Text »|PDF »
K. E. O'Reilly, F. Rojo, Q.-B. She, D. Solit, G. B. Mills, D. Smith, H. Lane, F. Hofmann, D. J. Hicklin, D. L. Ludwig, et al. (2006)
Cancer Res.
66, 1500-1508
|Abstract »|Full Text »|PDF »
Carcinogenesis and Metastasis Now in the Third Dimension--What's in It for Pathologists?.
C. Sonnenschein and A. M. Soto (2006)
Am. J. Pathol.
168, 363-366
|Full Text »|PDF »
Preferential Dependence of Breast Cancer Cells versus Normal Cells on Integrin-Linked Kinase for Protein Kinase B/Akt Activation and Cell Survival.
A. A. Troussard, P. C. McDonald, E. D. Wederell, N. M. Mawji, N. R. Filipenko, K. A. Gelmon, J. E. Kucab, S. E. Dunn, J. T. Emerman, M. B. Bally, et al. (2006)
Cancer Res.
66, 393-403
|Abstract »|Full Text »|PDF »
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors..
I. K. Mellinghoff, M. Y. Wang, I. Vivanco, D. A. Haas-Kogan, S. Zhu, E. Q. Dia, K. V. Lu, K. Yoshimoto, J. H.Y. Huang, D. J. Chute, et al. (2005)
N. Engl. J. Med.
353, 2012-2024
|Abstract »|Full Text »|PDF »
Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non-Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials.
D. W. Bell, T. J. Lynch, S. M. Haserlat, P. L. Harris, R. A. Okimoto, B. W. Brannigan, D. C. Sgroi, B. Muir, M. J. Riemenschneider, R. B. Iacona, et al. (2005)
J. Clin. Oncol.
23, 8081-8092
|Abstract »|Full Text »|PDF »
Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
R. Chen, M. J. Keating, V. Gandhi, and W. Plunkett (2005)
Blood
106, 2513-2519
|Abstract »|Full Text »|PDF »
An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor.
S. Kobayashi, H. Ji, Y. Yuza, M. Meyerson, K.-K. Wong, D. G. Tenen, and B. Halmos (2005)
Cancer Res.
65, 7096-7101
|Abstract »|Full Text »|PDF »
Epidermal Growth Factor Receptors Harboring Kinase Domain Mutations Associate with the Heat Shock Protein 90 Chaperone and Are Destabilized following Exposure to Geldanamycins.
T. Shimamura, A. M. Lowell, J. A. Engelman, and G. I. Shapiro (2005)
Cancer Res.
65, 6401-6408
|Abstract »|Full Text »|PDF »
Retinoid Targeting of Different D-Type Cyclins through Distinct Chemopreventive Mechanisms.
Y. Ma, Q. Feng, D. Sekula, J. A. Diehl, S. J. Freemantle, and E. Dmitrovsky (2005)
Cancer Res.
65, 6476-6483
|Abstract »|Full Text »|PDF »
Tyrosine Kinases as Targets for Cancer Therapy.
D. S. Krause and R. A. Van Etten (2005)
N. Engl. J. Med.
353, 172-187
|Full Text »|PDF »
Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras-Directed Therapy.
J. B. Fleming, G.-L. Shen, S. E. Holloway, M. Davis, and R. A. Brekken (2005)
Mol. Cancer Res.
3, 413-423
|Abstract »|Full Text »|PDF »
The NF1 tumor suppressor critically regulates TSC2 and mTOR.
C. M. Johannessen, E. E. Reczek, M. F. James, H. Brems, E. Legius, and K. Cichowski (2005)
PNAS
102, 8573-8578
|Abstract »|Full Text »|PDF »
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
E. L. Kwak, R. Sordella, D. W. Bell, N. Godin-Heymann, R. A. Okimoto, B. W. Brannigan, P. L. Harris, D. R. Driscoll, P. Fidias, T. J. Lynch, et al. (2005)
PNAS
102, 7665-7670
|Abstract »|Full Text »|PDF »
Systemic Therapy of Advanced Bronchioloalveolar Cell Carcinoma: Challenges and Opportunities.
V. A. Miller, F. R. Hirsch, and D. H. Johnson (2005)
J. Clin. Oncol.
23, 3288-3293
|Abstract »|Full Text »|PDF »
Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer.
